Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.
Stem Cell Res Ther. 2018 May 24;9(1):149. doi: 10.1186/s13287-018-0898-x.
Allogeneic mesenchymal stem cell (MSC) transplantation has recently become a promising therapy for patients with systemic lupus erythematosus (SLE). MSCs are a kind of multipotent stem cell than can efficiently modulate both innate and adaptive immune responses, yet those from SLE patients themselves fail to maintain the balance of immune cells, which is partly due to the abnormal genetic background. Clarifying genetic factors associated with MSC dysfunction may be helpful to delineate SLE pathogenesis and provide new therapeutic targets. In this review, the scientific evidence on the genetic contribution to MSC dysfunction in SLE is summarized.
同种异体间充质干细胞（MSC）移植最近已成为治疗系统性红斑狼疮（SLE）患者的一种有前途的疗法。间充质干细胞是一种多能干细胞，能够有效地调节先天和适应性免疫反应，但来自 SLE 患者自身的间充质干细胞未能维持免疫细胞的平衡，这在一定程度上是由于异常的遗传背景。阐明与间充质干细胞功能障碍相关的遗传因素可能有助于阐明 SLE 的发病机制，并提供新的治疗靶点。在这篇综述中，总结了有关 SLE 中 MSC 功能障碍的遗传贡献的科学证据。
